Dissociative Research Chemicals: A Complete Guide to DCK, 2F-NENDCK & the NMDA Class

Dissociative compounds have been central to neuroscience research since the discovery of ketamine's anaesthetic and antidepressant properties in the mid-twentieth century. The NMDA (N-methyl-D-aspartate) receptor — the primary target of this compound class — is implicated in learning and memory, chronic pain processing, depression, and schizophrenia.

Research into novel dissociative analogs offers a means to probe these receptor systems with greater selectivity than ketamine itself allows, and in many European jurisdictions, these analogs remain legal for research purposes where ketamine does not.

This guide covers the leading dissociative research chemicals available through EuroChems in 2026.

---

The NMDA Receptor: Why It Matters

NMDA receptors are ionotropic glutamate receptors that play a fundamental role in synaptic plasticity — the cellular mechanism underlying learning and memory. They are ligand-gated ion channels that require two conditions to open: binding of the agonist glutamate AND membrane depolarisation (the so-called "voltage dependency").

Dissociative compounds act as NMDA receptor antagonists — they block the receptor's ion channel, preventing calcium influx. This mechanism:

1. Produces anaesthetic and analgesic effects at high concentrations
2. Induces dissociative states at sub-anaesthetic doses
3. Has rapid antidepressant effects (the basis of ketamine infusion therapy)
4. Modulates dopamine signalling indirectly

Understanding which structural modifications to ketamine and related compounds affect receptor affinity, selectivity, and dissociation kinetics is the core research application for this compound class.

---

Key Dissociative Research Chemicals

DCK — Deschloroketamine (2-Phenyl-2-(methylamino)cyclohexan-1-one)

CAS: 4631-27-0
Molecular Formula: C13H17NO
Molecular Weight: 203.28 g/mol
Also Known As: 2'-Oxo-PCM, O-PCM

DCK is structurally identical to ketamine with the exception that the chlorine substituent on the phenyl ring has been removed (hence "des-chloro"). This seemingly minor change produces meaningful differences in pharmacokinetics and potency.

Pharmacological Profile:

• Primary target: NMDA receptor (non-competitive antagonist)
• Secondary targets: Opioid receptors (mu, sigma), D2 dopamine
• Potency: Approximately 2–4× more potent than ketamine by weight
• Duration: 3–6 hours (longer than ketamine's 1–2 hour clinic duration)
• Onset: 15–30 minutes (oral)

Research Value: DCK is particularly useful for studying the role of the chlorine substituent in ketamine pharmacology — specifically how its removal affects receptor binding kinetics and duration of action. The increased potency and extended duration make it a useful comparator in NMDA antagonism studies.

Legal Status (March 2026): Unscheduled in the Netherlands, Czech Republic, and several other EU countries. Controlled in Germany under NpSG. Always verify current status in your jurisdiction.

---

2F-NENDCK — Canetone (2-(2-Fluorophenyl)-2-(ethylamino)cyclohexan-1-one)

CAS: 2709972-56-3
Molecular Formula: C14H18FNO
Molecular Weight: 251.30 g/mol
Common Names: Canetone, 2F-NENDCK, Fluoroethylnorketamine

2F-NENDCK (trade name: Canetone) is one of the most novel dissociatives in the current research chemical market. It combines a fluorine substitution at the 2-position of the phenyl ring (as in 2-FDCK) with an N-ethyl group (replacing ketamine's N-methyl), producing a compound with a distinct pharmacological fingerprint.

Pharmacological Profile:

• Primary target: NMDA receptor antagonist
• The fluorine atom increases lipophilicity and potentially affects brain penetration
• N-ethyl substitution modifies receptor binding kinetics vs. N-methyl compounds
• Duration: 3–5 hours
• Onset: 20–40 minutes

Why Researchers Are Interested: The 2-fluorophenyl modification has precedent in established research (2-FDCK has been extensively studied). Combining this with N-ethyl substitution makes 2F-NENDCK a genuinely novel pharmacological entity with limited prior characterisation — making it ideal for first-in-class receptor profiling studies.

Legal Status (March 2026): Novel enough to remain unscheduled in most EU jurisdictions as of early 2026. Verify before ordering.

---

O-PCE — O-Desmethyltramadol Phenylcyclohexylamine (2-(3-Methoxyphenyl)-2-(ethylamino)cyclohexan-1-one)

CAS: 6740-85-8
Molecular Formula: C15H21NO2
Molecular Weight: 263.33 g/mol
Also Known As: Eticyclidone, 2'-Oxo-PCE, Methoxetamine successor

O-PCE is the current generation successor to methoxetamine (MXE) — a research chemical that gained significant attention before being controlled across the EU. The key structural difference is the repositioning of the methoxy group from the 3-position of the phenyl ring, affecting receptor selectivity.

Pharmacological Profile:

• NMDA antagonist (primary)
• Sigma-1 receptor agonist (significant — distinguishes it from ketamine)
• Serotonin reuptake inhibition (moderate)
• Duration: 3–5 hours
• Onset: 20–40 minutes

Research Value: O-PCE's sigma-1 receptor activity makes it particularly interesting for researchers studying the intersection of NMDA antagonism and sigma receptor pharmacology — a combination relevant to antidepressant mechanisms and neuroplasticity research.

---

Dissociative Compound Comparison Table

| Compound | NMDA Affinity | Duration | Other Targets | Legal (NL/CZ) | Research Focus | |---|---|---|---|---|---| | DCK | High | 3–6 hrs | Opioid, D2 | ✅ | Cl-removal effects on ketamine | | 2F-NENDCK | High (estimated) | 3–5 hrs | Novel — under study | ✅ | Novel fluoroethyl NMDA research | | O-PCE | High | 3–5 hrs | Sigma-1, SERT | ✅ | Multi-receptor dissociative | | Ketamine | High | 1–2 hrs | Opioid, sigma | ⚠️ Scheduled | Reference standard |

---

NMDA Receptor Research Applications

Depression and Antidepressant Mechanisms

The 2012 discovery that subanesthetic ketamine produces rapid antidepressant effects (within hours, persisting for days) transformed understanding of depression pharmacology. NMDA antagonism triggers AMPA receptor upregulation and BDNF release via mTORC1 signalling — a pathway distinct from all classic antidepressants.

Dissociative research chemicals allow researchers to:

• Map which structural features of ketamine are required for antidepressant vs. dissociative effects
• Compare receptor kinetics across analogs
• Study sigma-1 and opioid receptor contributions (O-PCE is particularly relevant here)

Pain Research

Ketamine's analgesic mechanism involves NMDA receptor blockade in the spinal cord dorsal horn, reducing central sensitisation. Novel dissociative analogs with different CNS penetration profiles (affected by lipophilicity, which fluorination alters) may show differential spinal vs. supraspinal effects — a key research question.

Synaptic Plasticity and Memory

NMDA receptors are the molecular "coincidence detectors" underlying Hebbian learning. Controlled blockade at different receptor subunit levels (GluN2A vs. GluN2B selective antagonists) produces distinct effects on long-term potentiation. This is an active area where novel analogs provide useful tools.

---

Storage and Handling

Dissociative research chemicals are typically available as HCl salts:

• Temperature: 2–8°C for routine storage; -20°C for long-term archival
• Light: Protect from UV
• Moisture: Store sealed with desiccant
• Container: Amber glass or HDPE — avoid contact with reactive plastics
• Stability: Arylcyclohexylamine salts are relatively stable under dry, cool conditions; no special precautions beyond standard lab hygiene

---

Analytical Verification

Before incorporating any dissociative research chemical into an assay:

1. Ehrlich Reagent — Dissociatives do not react (helps differentiate from tryptamines)
2. Mandelin Reagent — Produces orange to brown colouration for ketamine-class compounds
3. GC-MS or LC-MS — Definitive identification; all EuroChems compounds supplied with COA
4. NMR — For structural confirmation in academic laboratory settings

---

Legal and Compliance Notes

Dissociatives occupy varying positions across EU law. The Netherlands and Czech Republic maintain compound-specific scheduling, leaving several analogs unscheduled. Germany's NpSG captures most established dissociatives under family-based provisions.

EuroChems maintains a live legal database and only ships compounds to jurisdictions where they are currently legal. All products are labelled for in vitro research use only.

---

Disclaimer: All information is for educational and research purposes only. Not for human consumption. Always verify legal status in your country before ordering.

Related Reading:

• European Regulatory Guide 2026
• Research Chemicals Market Surge 2026
• Browse Dissociatives at EuroChems